Pfizer/Hospira's Biosimilar Pipeline: Substantial Overlap, Limited Divestiture So Far

All five biosimilars in Pfizer’s clinical pipeline overlap with those in Hospira’s, but even though only infliximab is required to be divested, the others could also be sold off to reach cost-saving targets.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet